clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Fibrosis D005355 23 associated lipids
Periodontitis D010518 22 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Ischemia D007511 18 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Bronchial Spasm D001986 18 associated lipids
Dermatomycoses D003881 17 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Synovitis D013585 15 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Radiation Injuries D011832 14 associated lipids
Rosacea D012393 13 associated lipids
Bradycardia D001919 13 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Abscess D000038 13 associated lipids
Urticaria D014581 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Endophthalmitis D009877 12 associated lipids
Wound Infection D014946 12 associated lipids
Otitis Media D010033 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Exanthema D005076 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock, Septic D012772 11 associated lipids
Influenza, Human D007251 11 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Pancreatitis D010195 10 associated lipids
Dyspnea D004417 10 associated lipids
Hearing Disorders D006311 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Osteomyelitis D010019 10 associated lipids
Hemophilia A D006467 10 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Cross Infection D003428 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Urination Disorders D014555 9 associated lipids
Urethritis D014526 9 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ruiz-González A et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. 2007 Respirology pmid:17207036
Ding FM et al. Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection. 2012 Respirology pmid:22404374
Strouvalis I et al. Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence. 2018 Respirology pmid:29741298
Sawabuchi T et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. 2009 Respirology pmid:19909463
Okimoto N et al. Clinical features of Q fever pneumonia. 2004 Respirology pmid:15182283
Kikuchi E et al. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. 2008 Respirology pmid:18339019
Isozumi R et al. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae. 2009 Respirology pmid:19732389
Liapakis IE et al. Penetration of clarithromycin in experimental pleural empyema model fluid. 2005 May-Jun Respiration pmid:15942299
Rovira E et al. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. 1999 Respiration pmid:10516537
Huchon G How to manage the low-risk patient with lower respiratory tract infection? 1999 Respiration pmid:10577170
Kobashi Y and Matsushima T The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. 2007 Respiration pmid:16954651
Jouneau S et al. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. 2013 Respiration pmid:23095475
Fujiuchi S et al. Analysis of chest CT in patients with Mycobacterium avium complex pulmonary disease. 2003 Jan-Feb Respiration pmid:12584395
Persson CG and Uller L Resolution of cell-mediated airways diseases. 2010 Respir. Res. pmid:20540713
Ballard HO et al. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. 2007 Respir. Res. pmid:17550598
Amado-Rodríguez L et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. 2013 Respir. Res. pmid:23663489
Beigelman A et al. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. 2010 Respir. Res. pmid:20591166
du Toit LC et al. Tuberculosis chemotherapy: current drug delivery approaches. 2006 Respir. Res. pmid:16984627
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Legssyer R et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. 2006 Respir. Res. pmid:17064416
Kadota J et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. 2003 Respir Med pmid:12854636
Miravitlles M et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. 2005 Respir Med pmid:15950136
Lode H et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. 2003 Respir Med pmid:14561021
Niederman MS et al. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. 2006 Respir Med pmid:16531032
Hoeffken G et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. 2001 Respir Med pmid:11453311
Hagberg L et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. 2003 Respir Med pmid:12814146
Kohyama T et al. Clarithromycin inhibits fibroblast migration. 2008 Respir Med pmid:18701271
Abe M et al. A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. 1998 Respir Med pmid:9893782
Kobashi Y et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. 2007 Respir Med pmid:16750618
Simoens S et al. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. 2013 Respir Med pmid:23352223
Banerjee D et al. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. 2005 Respir Med pmid:15715188
Carbon C et al. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. 2006 Respir Med pmid:16376537
Yatera K et al. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. 2017 Respir Investig pmid:29153420
Higashi F et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. 2014 Respir Investig pmid:25169846
Suzuki K et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance. 2018 Respir Investig pmid:29325687
Heifets LB Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. 1994 Mar-Apr Res. Microbiol. pmid:7809471
Dautzenberg B Clinical trials in Mycobacterium avium therapy: lessons to take home. 1994 Mar-Apr Res. Microbiol. pmid:7809472
Horgen L et al. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. 1997 Res. Microbiol. pmid:9765852
Yajko DM In vitro activity of antimicrobial agents against the Mycobacterium avium complex inside macrophages from HIV1-infected individuals: the link to clinical response to treatment? 1992 Res. Microbiol. pmid:1455069
Sander P et al. Ribosomal drug resistance in mycobacteria. 1996 Jan-Feb Res. Microbiol. pmid:8761724
Kargar M et al. Real-time PCR for Helicobacter pylori quantification and detection of clarithromycin resistance in gastric tissue from patients with gastrointestinal disorders. 2012 Res. Microbiol. pmid:22177975
Komori T et al. Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. 1998 Res. Commun. Mol. Pathol. Pharmacol. pmid:9874281
Ives TJ et al. Disposition and functions of clarithromycin in human THP-1 monocytes during stimulated and unstimulated conditions. 2001 Res. Commun. Mol. Pathol. Pharmacol. pmid:12760488
Yatsunami J et al. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. 1997 Res Exp Med (Berl) pmid:9440137
Sharma H et al. Fortuitous vasculitis. 2012 Ren Fail pmid:22250755
Wen YK and Chen ML Crescentic glomerulonephritis associated with non-tuberculous mycobacteria infection. 2008 Ren Fail pmid:18350456
Itatsu T et al. Eradication of Helicobacter pylori in hemodialysis patients. 2007 Ren Fail pmid:17365917
Parola D et al. [Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia]. 2000 Recenti Prog Med pmid:10705778
Vaira D et al. [Treatment for Helicobacter pylori: current criteria]. 2007 Recenti Prog Med pmid:18044409
Palumbo E et al. [Mycoplasma pneumoniae encephalitis in immunocompetent child]. 2008 Recenti Prog Med pmid:18710062
Zautner AE Adenotonsillar disease. 2012 Recent Pat Inflamm Allergy Drug Discov pmid:22452646
Bergamaschi A et al. Recent Advances in the Treatment of Helicobacter pylori Infection. 2007 Recent Pat Antiinfect Drug Discov pmid:18221177
Campo SM et al. Antibiotic treatment strategies for Helicobacter pylori infection. 2007 Recent Pat Antiinfect Drug Discov pmid:18221161
Leonard S et al. Application of liquid chromatography/ion trap mass spectrometry to the characterization of the related substances of clarithromycin. 2006 Rapid Commun. Mass Spectrom. pmid:16991103
Calza P et al. Identification of the unknown transformation products derived from clarithromycin and carbamazepine using liquid chromatography/high-resolution mass spectrometry. 2012 Rapid Commun. Mass Spectrom. pmid:22730089
Kim HS et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. 2012 Radiology pmid:22371609
Ozdemir A et al. Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis. 2001 Quintessence Int pmid:12066673
Lin YH and Liu TC Mycobacterium chelonae infection involving the auricle. 2012 QJM pmid:21908384
Browne G et al. A potential role for keratinocyte growth factor and clarithromycin in the treatment of paraquat overdose. 2010 QJM pmid:20154068
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Burch LH and Picher M E-NTPDases in human airways: Regulation and relevance for chronic lung diseases. 2006 Purinergic Signal. pmid:18404479
Hasegawa N et al. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. 2009 Pulm Pharmacol Ther pmid:19061965
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Morinaga Y et al. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells. 2009 Pulm Pharmacol Ther pmid:19716898
Gao X et al. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. 2010 Pulm Pharmacol Ther pmid:19895898
Liu CP et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. 2014 Pulm Pharmacol Ther pmid:23518214
Nakamura M et al. Clarithromycin ameliorates pulmonary inflammation induced by short term cigarette smoke exposure in mice. 2015 Pulm Pharmacol Ther pmid:26363279
Martynova AV et al. Emergence of Haemophilus influenzae Strains in the Nasopharynx of Children with Tuberculosis. 2011 Pulm Med pmid:21766017
Rafii R et al. Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease. 2011 Pulm Med pmid:21660228
Figueiredo Bde C and Ibiapina Cda C The role of macrolides in noncystic fibrosis bronchiectasis. 2011 Pulm Med pmid:22292118
Warner A Clarithromycin--a precipitant for acute psychotic stress. 2000 Nov-Dec Psychosomatics pmid:11110120
Mermelstein HT Clarithromycin-induced delirium in a general hospital. 1998 Nov-Dec Psychosomatics pmid:9819955
Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. 2015 Psychopharmacology (Berl.) pmid:25510856
Härtig G et al. [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. 1999 Psychiatr Prax pmid:10457975
Mrozińska M [Legionellosis in three children--cases report]. 2005 Przegl Epidemiol pmid:16729426
Mach T and Zahradnik-Bilska J [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. 1999 Prz. Lek. pmid:10575912
Hydzik P et al. [Drug-induced erythrodermia complicated by multiorgan failure--case report]. 2011 Prz. Lek. pmid:22010450
Trzebiatowska I et al. [Psychosis caused by the treatment with clarithromycin--a case report]. 2011 Prz. Lek. pmid:22010468
Zwolińska-Wcisło M and Palka M [Principles of managing Helicobacter pylori infections. Guidelines of the European Society of Gastroenterology in Primary Health Care]. 2000 Prz. Lek. pmid:11293204
Thorley JA et al. Mechanisms of viral entry: sneaking in the front door. 2010 Protoplasma pmid:20446005
Sato Y et al. Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production. 2007 Prostaglandins Leukot. Essent. Fatty Acids pmid:17324565
Miyazaki M et al. Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12907132
Björkholm B et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11717398
Pfister P et al. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G. 2005 Proc. Natl. Acad. Sci. U.S.A. pmid:15795375
Fahey JW et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. 2002 Proc. Natl. Acad. Sci. U.S.A. pmid:12032331
Shmelev EI et al. [Clarythromycin in the treatment of exacerbations of chronic obstructive lung disease]. 2006 Probl Tuberk Bolezn Legk pmid:17002058
James GD et al. Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. 2013 Prim Care Respir J pmid:23839240
Kwan BY and Rabheru K Manic episode associated with clarithromycin in a patient with medically treated depression. 2012 Prim Care Companion CNS Disord pmid:22943025
Sellal A et al. [Maintenance treatment of cerebral toxoplasmosis in AIDS: role of clarithromycin-minocycline combination]. 1996 Presse Med pmid:8685115
Contios S et al. [Mycobacterium marinum tenosynovitis of the abductors]. 2005 Presse Med pmid:15962499
Saint-Marc T et al. [Mycobacterium avium intracellulare infections. Treatment with a clarithromycin-clofazimine combination. 18 cases]. 1993 Presse Med pmid:8121903
Guillemet C et al. [Clarithromycin-digoxin: an unrecognized interaction in some patients]. 1997 Presse Med pmid:9137381
Esvant H et al. [Primary prophylaxis of cerebral toxoplasmosis in AIDS with clarithromycin]. 1993 Presse Med pmid:8337221
de Masson A et al. Cavitary pulmonary disease in a patient treated with natalizumab. 2014 Presse Med pmid:24742610
Mégraud F [Helicobacter pylori: bacteriological aspects, diagnostic methods, and susceptibility to antibiotics]. 2008 Presse Med pmid:18261874
Songné B et al. [Buruli ulcer in Togo: 21 cases]. 2001 Presse Med pmid:11317927
Courillon-Mallet A [Treatment of Helicobacter pylori infection]. 2008 Presse Med pmid:18255253
Morlet-Barla N et al. [Severe hypoglycemia and recurrence caused by disopyramide-clarithromycin interaction]. 2000 Jul 8-15 Presse Med pmid:10938688
Olivier D [HIV: a guide on management of seropositive patients]. 2001 Presse Med pmid:11268903